Drugs / LCB84
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05941507 | Oct 2023 → Jan 2027 expected | cancer | LigaChem Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCB84 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05941507 ↗ |
| Modality | Monoclonal antibody | “TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug” NCT05941507 ↗ |
| Route | Intravenous | “IV infusion Q3W” NCT05941507 ↗ |